Citi Reinstates Coverage of Eli Lilly with Optimistic Outlook
Citi has renewed its analysis of Eli Lilly & Co., assigning a Buy rating with a target price of $1,060 per share. This decision marks the resumption of coverage after a temporary suspension, driven by improved forecasts for tirzepatide, Eli Lilly's promising treatment for diabetes and obesity.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
